دانلود مقاله ISI انگلیسی شماره 126908
ترجمه فارسی عنوان مقاله

پیش بینی کننده علایم منفی در فاز مزمن اسکیزوفرنیا: یک مطالعه مقطعی

عنوان انگلیسی
Predictors of negative symptoms in the chronic phase of schizophrenia: A cross-sectional study
کد مقاله سال انتشار تعداد صفحات مقاله انگلیسی
126908 2018 9 صفحه PDF
منبع

Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)

Journal : Psychiatry Research, Volume 262, April 2018, Pages 600-608

ترجمه کلمات کلیدی
جنون جوانی، علائم منفی، علائم مثبت، سن در شروع، ضد روانپزشکی غیرمعمول،
کلمات کلیدی انگلیسی
Schizophrenia; Negative symptoms; Positive symptoms; Age at onset; Atypical antipsychotics;
پیش نمایش مقاله
پیش نمایش مقاله  پیش بینی کننده علایم منفی در فاز مزمن اسکیزوفرنیا: یک مطالعه مقطعی

چکیده انگلیسی

This study was designed to investigate the relationship between negative symptoms and key indicators for long-term hospital stays among inpatients with schizophrenia. A further aim was to elucidate the clinical determinants of negative symptoms. The following were used as index factors: age, duration of illness, duration of hospitalization, age at onset, years of education, smoking status, body mass index, concentrations of serum triglycerides, total cholesterol, uric acid, QTc interval duration from electrocardiography, dose equivalents of antipsychotic and anticholinergic agents, neurocognitive function, drug-induced extrapyramidal symptoms, involuntary movements, and psychiatric symptoms. Spearman's rank correlation coefficients were calculated and regression analyses were performed to examine associations between these factors and negative symptoms. Positive symptoms correlated positively with negative symptoms as rated on the Brief Psychiatric Rating Scale. Age at onset correlated negatively with negative symptoms. Multiple regression analysis showed that dose equivalents of atypical antipsychotics and positive symptoms predicted negative symptoms. Increasing our understanding of these predictors as key indicators of the severity of negative symptoms may aid in the reconsideration of therapeutic programs for chronic schizophrenia.